Lisa Swanson, MD, JCAD’s Section Editor of Pediatric Dermatology, shares her thoughts on new research evaluating maximum-use conditions for topical ruxolitinib cream in pediatric patients (2 to 11 years) with atopic dermatitis.
Reference:
- Stein Gold L, Bissonnette R, Forman S, et al. A Maximum‐Use Trial of Ruxolitinib Cream in Children Aged 2–11 Years with Moderate to Severe Atopic Dermatitis. Am J Clin Dermatol. 2025, Jan 6.